russ2000_1429|BTX|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment
russ2000_1429|BTX|Long Name|1|1|Brooklyn ImmunoTherapeutics Inc Total Current Assets (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Inventories (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Net PP&E (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Total Liabilities (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Total Current Liabilities (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Total Deposits (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Book Value (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Retained Earnings (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Treasury Stock (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc EV to Revenues|Brooklyn ImmunoTherapeutics Inc EV to Earnings|Brooklyn ImmunoTherapeutics Inc EV to Free Cash Flow|Brooklyn ImmunoTherapeutics Inc EV to Assets (Quarterly)|Brooklyn ImmunoTherapeutics Inc PS Ratio|Brooklyn ImmunoTherapeutics Inc PE Ratio|Brooklyn ImmunoTherapeutics Inc Price to Book Value|Brooklyn ImmunoTherapeutics Inc PEG Ratio|Brooklyn ImmunoTherapeutics Inc Debt to Equity Ratio|Brooklyn ImmunoTherapeutics Inc Dividend Yield|Brooklyn ImmunoTherapeutics Inc Shareholder Yield (TTM)|Brooklyn ImmunoTherapeutics Inc Percent of Shares Outstanding Short|Brooklyn ImmunoTherapeutics Inc Total Receivables (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Total Payables (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Total Capital Stock (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Return on Invested Capital|Brooklyn ImmunoTherapeutics Inc Quality Ratio Score|Brooklyn ImmunoTherapeutics Inc Momentum Score|Brooklyn ImmunoTherapeutics Inc Beta (1Y)|Brooklyn ImmunoTherapeutics Inc Sustainable Growth Rate (TTM)|Brooklyn ImmunoTherapeutics Inc Institutional Investor Ownership Percentage|Brooklyn ImmunoTherapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Brooklyn ImmunoTherapeutics Inc Total Employees (Annual)|Brooklyn ImmunoTherapeutics Inc EPS Diluted (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc SG&A Expense (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Shares Outstanding|Brooklyn ImmunoTherapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Ordinary Shares Number (Quarterly)|Brooklyn ImmunoTherapeutics Inc Payout Ratio|Brooklyn ImmunoTherapeutics Inc Quick Ratio (Quarterly)|Brooklyn ImmunoTherapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Stock Buybacks (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Effective Tax Rate (TTM)|Brooklyn ImmunoTherapeutics Inc Return on Equity|Brooklyn ImmunoTherapeutics Inc Net Income (TTM) (USD)|Brooklyn ImmunoTherapeutics Inc Revenue (TTM) (USD)|Brooklyn ImmunoTherapeutics Inc Dividend Per Share (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Revenue (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Gross Profit (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Pre-Tax Income (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Net Income (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Net Interest Income (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Price (USD)|Brooklyn ImmunoTherapeutics Inc Total Return Price (USD)|Brooklyn ImmunoTherapeutics Inc Enterprise Value (USD)|Brooklyn ImmunoTherapeutics Inc 30-Day Average Daily Volume|Brooklyn ImmunoTherapeutics Inc 1 Year Price Returns (Daily)|Brooklyn ImmunoTherapeutics Inc Short Interest|Brooklyn ImmunoTherapeutics Inc PE Ratio (Forward)|Brooklyn ImmunoTherapeutics Inc PE Ratio (Forward 1y)|Brooklyn ImmunoTherapeutics Inc PS Ratio (Forward)|Brooklyn ImmunoTherapeutics Inc PS Ratio (Forward 1y)|Brooklyn ImmunoTherapeutics Inc Quarterly EPS Estimates (USD)|Brooklyn ImmunoTherapeutics Inc Quarterly Revenue Estimates (USD)|Brooklyn ImmunoTherapeutics Inc Quarterly EPS Surprise|Brooklyn ImmunoTherapeutics Inc Quarterly Revenue Surprise|Brooklyn ImmunoTherapeutics Inc Quarterly Actual EPS (USD)|Brooklyn ImmunoTherapeutics Inc Quarterly Actual Revenue (USD)|Brooklyn ImmunoTherapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Brooklyn ImmunoTherapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Brooklyn ImmunoTherapeutics Inc Price Target (USD)|Brooklyn ImmunoTherapeutics Inc Consensus Recommendation|Brooklyn ImmunoTherapeutics Inc Price Target Num Estimates|Brooklyn ImmunoTherapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Brooklyn ImmunoTherapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Brooklyn ImmunoTherapeutics Inc Research and Development Expense (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Land and Improvements (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Buildings and Improvements (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Other Properties (Quarterly) (USD)|Brooklyn ImmunoTherapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)
russ2000_1429|BTX|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric
russ2000_1429|BTX||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
russ2000_1429|BTX||5|5|91.5|91.5|0|91.5|91.5|91.5|91.5|91.5|0|91.5|91.5|0|0|0|1.44|0|0|0|1.43827160494|0|0|1.44298245614|0|15.3|91.5|91.5|91.5|0|0|0|0|0|30.6|109.6|0|109.6|109.6|18.9166666667|0|91.5|0|0|109.6|109.6|0|0|91.5|0|0|0|0|109.6|109.6|121.666666667|1.44298245614|1.44298245614|1.44|1.44221105528|0|15.3|0|0|0|0|0|92|0|0|0|0|39.6666666667|59.5|59.5|59.5|59.5|0|0|109.6|109.6|121.666666667|0|0|91.5|0
russ2000_1429|BTX||6|6|2|2|0|2|2|2|2|2|0|2|2|0|0|0|225|0|0|0|162|0|0|228|0|20|2|2|2|0|0|0|0|0|10|5|0|5|5|12|0|2|0|0|5|5|0|0|2|0|0|0|0|5|5|3|228|228|225|199|0|20|0|0|0|0|0|1|0|0|0|0|3|2|2|2|2|0|0|5|5|3|0|0|2|0
russ2000_1429|BTX||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly
russ2000_1429|BTX|202003|202003|202003||||||||||||||||||||||||||||||||||41.5142||-0.0246|1.0535||||||-0.0246|-0.3125||||||||-1.0192|-1.0192|||||||||||||||||||||||||-0.039|0.023|||||
russ2000_1429|BTX|202006|202006|202006||||||||||||||||||||||||||||||||||41.5142||-0.049|1.0341||||||-0.049|-3.5462||||||||-2.0334|-2.0334|||||||||||||||||||||||||0.9851|0.0246|||||
russ2000_1429|BTX|202009|202009|202009||||||||||||||||||||||||||||||||||41.5142||-0.0487|1.0841||||||-0.0487|0||||||||-2.0201|-2.0201|-0.0126||||||||||||||||||||||||0.9235|0.0253|0.0126||||
russ2000_1429|BTX|202103|202103|202103|8.7136|8.4099||2.5922|8.9037|25.1194|3.902|21.2174||-4.4221|-55.0831||||-14.7905|||||||0||0.1856|0.0534|1.812|0.2083||||||0.37|27.7994||-0.64|1.6366|41.506||41.506|||-0.1168|-10.4751|||-22.7751|||||-17.7023|-17.7023||3.72|3.72|146.7131|||77048||||||||||||||||||1.5196|0.0949||||2.3231|
russ2000_1429|BTX|202104|202103|202103|||||||||||||||-207.8861|||||||0||2.2596|||||||||0.6477|||||41.5621|||||||||||||||||49.8|49.8|2062.1033|||939153||||||||||||||||||||||||
russ2000_1429|BTX|202105|202103|202103|||||||||||||||-61.1903|||||||0||1.5641|||||||||0.6011|||||42.6847|||||||||||||||||14.4|14.4|606.9704|11946558.5333||667610||||||||||||||||||||||||
russ2000_1429|BTX|202106|202106|202106|51.9412|50.1647||3.3498|8.9037|29.5268|7.6845|21.8423||35.1821|-65.1762||||-50.9027||||22.8861|||0||1.9521|0.0233|3.6793|0.2243||||||15.6608|42.4482||-0.24|4.6204|44.7074||44.7074|||-0.2388|-48.5498|||-31.8412|||||-10.0853|-10.0853||18.01|18.01|755.7363|5887289.2333||872718||||||||||||||||||5.3928|0.1173||||3.3498|
russ2000_1429|BTX|202107|202106|202106|||||||||||||||-36.7038||||16.8942|||0||3.6457|||||||||13.5986|||||51.7296|||||||||||||||||11.49|11.49|544.9291|2720604.9||1885929||||||||||||||||||||||||
russ2000_1429|BTX|202108|202106|202106|||||||||||||||-38.7246||||17.747|||0||2.0766|||||||||13.2619|||||51.7296|||||||||||||||||12.07|12.07|574.9323|977140.8||1074232||||||||||||||||||||||||
russ2000_1429|BTX|202109|202109|202109|25.7583|24.3818||3.2128|8.9037|26.3541|4.5605|21.7935||13.0395|-151.2315||||-24.1221||||37.1185|||0||1.6108|0.0233|0.9963|0.261||||||15.0771|50.544||-1.7|4.2582|52.0438||52.0438|||-0.1113|-3.5005|||-115.8631|||||-86.0553|-86.0553|-0.0328|9.3|9.3|460.0363|874175.3||838347||||||0||||0||||||||1.4667|0.1234|0.0202|||3.2128|
russ2000_1429|BTX|202110|202109|202109|||||||||||||||-21.9935||||34.0053|||0||1.4556|||||||||16.0527||||||||||||||||||||||8.52|8.52|419.4421|598926.2333||757539|||||||||||0|0|20|2|1|||||||||
russ2000_1429|BTX|202111|202109|202109|||||||||||||||-14.9802||||23.7479|||0||1.5812|||||||||16.1939|||||52.0438|||||||||||||||||5.95|5.95|285.6896|536449.2||822921||||||||||||||||||||||||
russ2000_1429|BTX|202112|202112|202112|||||||||||||||-10.1227||||16.6435|||0||3.8763|||||||||18.2929||||||||||||||||||||||4.17|4.17|193.0516|604311.2667||2017389||||||0|||||0|0|14.5|1.5|2|||||||||
russ2000_1429|BTX|202201|202112|202112|||||||||||||||-6.1658||||10.8562|||0||4.0301|||||||||14.8688||||||||||||||||||||||2.72|2.72|117.5881|503030.7||2097427||||||||||||||||||||||||
russ2000_1429|BTX|202202|202112|202112|||||||||||||||-4.774||||8.8206|||0|||||||||||||||||||||||||||||||||2.21|2.21|91.0457|381732.8667|||||||||||||0|0|9|1.5|2|||||||||